치료 불응성 성인형 스틸병: 아나킨라 사용 후 임상 호전을 보인 증례 보고
Two Cases of Refractory Adult-Onset Still’s Disease Responding to Anakinra
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
성인형 스틸병은 전신적 염증 질환으로 기존의 치료에 반응하지 않는 경우가 드물지 않다. 인터루킨-1 길항제인anakinra는 불응성 성인형 스틸병의 대체 치료로 제시되고있다. 저자들은 아나킨라 치료로 임상 호전을 보인 두 명의불응성 성인형 스틸병 환자를 경험하였기에 한국에서 처음으로 이를 보고하는 바이다.
Abstract
Adult-onset Still’s disease (AOSD) is a systemic inflammatory disorder with variable clinical features. The interleukin (IL)-1 receptor antagonist anakinra has been proposed as an alternative effective treatment in refractory AOSD. We report, for the first time in Korea, two cases of refractory AOSD in which anakinra treatment produced a clinical response. The first patient had frequent clinical flare-ups with fever, sore throat, myalgia, and pleuritic chest pain despite treatment with methotrexate and etanercept. In the second patient, treatments with various immunosuppressive agents failed to control the disease activity. Treatment with anakinra 100 mg/day was initiated in both cases. A complete clinical remission and improvement in the laboratory parameters were observed. The steroid dose was tapered without further clinical flare-ups. Anakinra appears to be an effective alternative treatment modality in patients with AOSD refractory to conventional disease-modifying anti-rheumatic drugs and corticosteroid therapy. (Korean J Med 2012;82:520-524)
참고문헌 (15)
- Kalliolias GD, "The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis", Expert Opin Investig Drugs, 17, pp.349~359 (2008)
- Chen DY, "Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease", Ann Rheum Dis, 63, pp.1300~1306 (2004)
- Fitzgerald AA, "Rapid responses to anakinra in patients with refractory adult-onset Still's disease", Arthritis Rheum, 52, pp.1794~1803 (2005)
- Pouchot J, "Adult Still's disease: manifestations, disease course, and outcome in 62 patients", Medicine (Baltimore), 70, pp.118~136 (1991)
- 최정희, "Serum cytokine profiles in patients with adult onset Still`s disease", JOURNAL OF RHEUMATOLOGY, 30, pp.2422~2427, J RHEUMATOL PUBL CO
- Pascual V, "Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade", J Exp Med, 201, pp.1479~1486 (2005)
- Efthimiou P, "Diagnosis and management of adult onset Still's disease", Ann Rheum Dis, 65, pp.564~572 (2006)
- Aikawa NE, "Is anti-TNF switching in refractory Still's disease safe and effective?", Clin Rheumatol, 30, pp.1129~1134 (2011)
- Iwamoto M, "Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease", Arthritis Rheum, 46, pp.3388~3389 (2002)
- Lanza F, "Prolonged remission state of refractory adult onset Still's disease following CD34-selected autologous peripheral blood stem cell transplantation", Bone Marrow Transplant, 25, pp.1307~1310 (2000)
- Kim HA, "Therapeutic responses and prognosis in adult-onset Still's disease", Rheumayol Int (2011)
- Kalliolias GD, "Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial", Ann Rheum Dis, 66, pp.842~843 (2007)
- Lequerré T, "Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France", Ann Rheum Dis, 67, pp.302~308 (2008)
- Mertens M, "Anakinra for rheumatoid arthritis: a systematic review", J Rheumatol, 36, pp.1118~1125 (2009)
- Maier J, "Effective treatment of steroid refractory adult‐onset Still's disease with anakinra", J Rheumatol, 35, pp.939~941 (2008)